KUX 1151

Drug Profile

KUX 1151

Alternative Names: KUX-0511; KUX-1151

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kissei Pharmaceutical
  • Class Antigouts
  • Mechanism of Action SLC22A12 protein inhibitors; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Gout; Hyperuricaemia

Most Recent Events

  • 01 Jul 2014 Phase-II clinical trials in Gout in Japan (PO)
  • 01 Jul 2014 Phase-II clinical trials in Hyperuricaemia in Japan (PO)
  • 24 Dec 2013 KUX 1151 licensed to Pfizer worldwide, excluding Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top